Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart < sup > ® < /sup > Injector: Results of the Prospective Cohort Study REBIFLECT

CONCLUSION: Treatment adherence with the Rebismart® device was generally very high, consistent with other non-interventional studies. The first reflection talk supported by RebiSmart® induces excellent adherence, stabilized by repetition. Reflection to patients of subcutaneous interferon beta-1a treatment monitored by RebiSmart® is recommended to ensure prolonged strong treatment adherence.PMID:35428903 | DOI:10.1007/s12325-022-02100-w

Source: Adv Data - April 16, 2022 Category: Epidemiology Authors: Peter Rieckmann Tjalf Ziemssen Iris-Katarina Penner Alaleh Raji Torsten Wagner Joachim Richter Uwe K Zettl Source Type: research